https://ionctura.threethirtystudio.co.uk/news-views/ 2024-09-19T10:06:45+00:00 https://ionctura.threethirtystudio.co.uk/the-pi3k%ce%b4-inhibitor-roginolisib-ioa-244-preserves-t-cell-function-and-activity-2/ 2026-02-03T09:05:16+00:00 https://ionctura.threethirtystudio.co.uk/drug-discovery-world-ash-2025-combined-focus-on-myelofibrosis/ 2026-01-13T08:32:00+00:00 https://ionctura.threethirtystudio.co.uk/drug-discovery-world-autotaxin-inhibition-unlocking-new-frontiers-in-cancers-and-beyond/ 2026-01-13T08:31:18+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-ceo-to-present-at-the-2026-j-p-morgan-healthcare-conference/ 2026-01-09T13:52:56+00:00 https://ionctura.threethirtystudio.co.uk/the-selective-pi3k%ce%b4-inhibitor-roginolisib-synergizes-with-ruxolitinib-against-progenitor-cells-from-naive-and-jaki-refractory-resistant-patients-with-myelofibrosis/ 2025-12-16T09:55:56+00:00 https://ionctura.threethirtystudio.co.uk/trial-in-progress-a-study-of-roginolisib-in-combination-with-ruxolitinib-in-patients-with-myelofibrosis-who-are-unresponsive-to-jak-inhibitors-hema-med/ 2025-12-16T09:55:28+00:00 https://ionctura.threethirtystudio.co.uk/pla%cf%84form-a-multicenter-multi-arm-academic-platform-trial-evaluating-novel-agents-and-combinations-in-relapsed-or-refractory-peripheral-t-cell-lymphomas/ 2025-12-16T09:55:12+00:00 https://ionctura.threethirtystudio.co.uk/roginolisib-ioa-244-an-orally-bioavailable-selective-pi3k%ce%b4-inhibitor-in-combination-with-venetoclax-and-rituximab-in-patients-with-relapsed-chronic-lymphocytic-leukemia-cll/ 2025-12-16T09:54:54+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-initiates-phase-i-ii-trial-in-patients-with-myelofibrosis-ahead-of-new-non-clinical-data-at-ash/ 2025-12-09T09:52:35+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-data-at-aacr-demonstrates-unique-mechanism-of-action-for-clinical-stage-autotaxin-inhibitor-ioa-289-2/ 2025-11-21T13:53:54+00:00 https://ionctura.threethirtystudio.co.uk/characterization-and-translational-development-of-ioa-289-a-novel-autotaxin-inhibitor-for-the-treatment-of-solid-tumors/ 2025-11-21T13:53:40+00:00 https://ionctura.threethirtystudio.co.uk/ioa-289-an-orally-available-type-iv-autotaxin-inhibitor-ameliorates-steatosis-and-fibrosis-in-a-progressive-preclinical-murine-nash-model/ 2025-11-21T13:53:27+00:00 https://ionctura.threethirtystudio.co.uk/autotaxin-inhibition-with-ioa-289-decreases-breast-tumor-growth-in-mice-whereas-knockout-of-autotaxin-in-adipocytes-does-not/ 2025-11-21T13:53:08+00:00 https://ionctura.threethirtystudio.co.uk/autotaxin-inhibitor-ioa-289-reduces-gastrointestinal-cancer-progression-in-preclinical-models/ 2025-11-21T13:52:58+00:00 https://ionctura.threethirtystudio.co.uk/safety-and-clinical-efficacy-of-cambritaxestat-ioa-289-a-novel-autotaxin-inhibitor-plus-gemcitabine-and-nab-paclitaxel-gnp-in-patients-with-previously-untreated-metastatic-pancreatic-ductal-aden/ 2025-11-21T13:52:35+00:00 https://ionctura.threethirtystudio.co.uk/safety-and-clinical-efficacy-of-ioa-289-a-novel-autotaxin-inhibitor-plus-gemcitabine-and-nabpaclitaxel-gnp-in-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-mpdac/ 2025-11-21T13:52:16+00:00 https://ionctura.threethirtystudio.co.uk/non-clinical-toxicology-evaluation-of-the-novel-non-atp-competitive-oral-pi3-kinase-delta-inhibitor-roginolisib/ 2025-11-21T13:50:58+00:00 https://ionctura.threethirtystudio.co.uk/autotaxin-secretion-is-a-stromal-mechanism-of-adaptive-resistance-to-tgf%ce%b2-inhibition-in-pancreatic-ductal-adenocarcinoma/ 2025-11-21T13:50:48+00:00 https://ionctura.threethirtystudio.co.uk/safety-and-clinical-efficacy-of-roginolisib-ioa-244-the-first-oral-allosteric-modulator-of-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4/ 2025-11-21T13:50:35+00:00 https://ionctura.threethirtystudio.co.uk/novel-pi3k%ce%b4-inhibitor-roginolisib-synergizes-with-the-bcl-2-inhibitor-venetoclax-in-hematological-malignancies/ 2025-11-21T13:50:24+00:00 https://ionctura.threethirtystudio.co.uk/high-levels-of-autotaxin-and-lysophosphatidic-acid-predict-poor-outcome-in-treatment-of-resectable-gastric-carcinoma/ 2025-11-21T13:47:57+00:00 https://ionctura.threethirtystudio.co.uk/patient-derived-tumor-cells-identify-mechanistically-rational-combinations-for-the-pi3k%ce%b4-inhibitor-roginolisib-in-solid-and-hematologic-malignancies/ 2025-11-21T13:47:22+00:00 https://ionctura.threethirtystudio.co.uk/highly-selective-allosteric-modulator-of-the-phosphoinositide-3-kinase-data-pi3k%ce%b4-roginolisib-ioa-244-in-a-dose-escalation-study-of-patients-with-refractory-relapsed-follicular-lymphoma-fl/ 2025-11-21T13:46:05+00:00 https://ionctura.threethirtystudio.co.uk/first-in-human-fih-phase-i-dose-escalation-study-part-a-of-the-first-oral-allosteric-modulator-of-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4-roginolisib-in-patients-with-advanced-cance/ 2025-11-21T13:45:48+00:00 https://ionctura.threethirtystudio.co.uk/ioa-244-is-a-non-atp-competitive-highly-selective-tolerable-pi3k-delta-inhibitor-that-targets-solid-tumors-and-breaks-immune-tolerance/ 2025-11-21T13:45:20+00:00 https://ionctura.threethirtystudio.co.uk/long-term-safety-evaluation-of-roginolisib-formerly-ioa-244-a-highly-selective-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4-in-a-phase-i-first-in-human-fih-study/ 2025-11-21T13:45:08+00:00 https://ionctura.threethirtystudio.co.uk/characterization-of-the-non-atp-competitive-pi3k%ce%b4-inhibitor-ioa-244-in-lymphoma-models-from-single-agent-to-combination-screen-and-clinical-investigation/ 2025-11-21T13:44:51+00:00 https://ionctura.threethirtystudio.co.uk/safety-and-clinical-activity-of-ioa-244-a-highly-selective-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4-in-a-phase-i-first-in-human-fih-study-study-part-a/ 2025-11-21T13:44:33+00:00 https://ionctura.threethirtystudio.co.uk/ioa-244-is-a-non-atp-competitive-highly-selective-tolerable-phosphoinositide-3-linase-delta-inhibitor-that-directly-targets-solid-tumors-and-breaks-immune-tolerance/ 2025-11-21T13:44:16+00:00 https://ionctura.threethirtystudio.co.uk/non-atp-competitive-inhibition-of-pi3%ce%b4-with-ioa-244-shows-anti-lymphoma-activity/ 2025-11-21T13:43:58+00:00 https://ionctura.threethirtystudio.co.uk/safety-pharmacokinetic-pk-pharmacodynamic-pd-and-activity-of-the-highly-selective-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4-inhibitor-ioa-244-in-patients-with-follicular-lymphoma-f/ 2025-11-21T13:43:47+00:00 https://ionctura.threethirtystudio.co.uk/first-in-human-fih-phase-i-study-of-the-highly-selective-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4-inhibitor-ioa-244-in-patients-with-advanced-cancer-safety-activity-pharmacokinetic/ 2025-11-21T13:43:17+00:00 https://ionctura.threethirtystudio.co.uk/tlr-x-ioa-359-attenuates-steatosis-and-fibrosis-in-a-preclinical-nash-model/ 2025-11-21T13:41:35+00:00 https://ionctura.threethirtystudio.co.uk/preclinical-activity-of-novel-tgf-beta-receptor-i-kinase-inhibitors-ioa-359-and-ioa-360-for-treatment-of-anemia-in-mds-aml/ 2025-11-21T13:39:24+00:00 https://ionctura.threethirtystudio.co.uk/the-highly-selective-and-oral-phosphoinositide-3-kinase-delta-pi3k-%ce%b4-inhibitor-roginolisib-induces-apoptosis-in-mesothelioma-cells-and-increases-immune-effector-cell-composition/ 2025-11-21T13:38:23+00:00 https://ionctura.threethirtystudio.co.uk/1305-2/ 2025-11-21T13:37:36+00:00 https://ionctura.threethirtystudio.co.uk/roginolisib-ioa-244-a-first-oral-allosteric-modulator-of-phosphoinositide-3-kinase-inhibitor-delta-pi3k%ce%b4-in-patients-with-metastatic-uveal-melanoma/ 2025-11-21T13:36:51+00:00 https://ionctura.threethirtystudio.co.uk/transforming-growth-factor-beta-receptor-type-i-tgf-%ce%b2ri-kinase-inhibitors-ioa-359-and-ioa-360-stimulate-erythropoiesis-in-mds/ 2025-11-21T13:31:51+00:00 https://ionctura.threethirtystudio.co.uk/molecular-profiling-of-the-pi3k%ce%b4-inhibitor-roginolisib-in-metastatic-uveal-melanoma-and-its-correlation-with-clinical-outcomes/ 2025-11-21T13:30:50+00:00 https://ionctura.threethirtystudio.co.uk/cll-societys-2024-clinical-scholar-award-dr-jennifer-brown/ 2025-11-13T09:33:00+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-debuts-cambritaxestat-ioa-289-clinical-data-in-patients-with-pancreatic-cancer-at-esmo/ 2025-10-14T09:25:27+00:00 https://ionctura.threethirtystudio.co.uk/the-pi3k%ce%b4-inhibitor-roginolisib-ioa-244-preserves-t-cell-function-and-activity/ 2025-09-11T11:00:53+00:00 https://ionctura.threethirtystudio.co.uk/novel-pi3k%ce%b4-inhibitor-roginolisib-synergizes-with-venetoclax-in-hematologic-malignancies/ 2025-09-09T14:09:39+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-expands-roginolisib-trials-to-the-us-advancing-multi-indication-strategy-in-oncology/ 2025-09-09T06:59:47+00:00 https://ionctura.threethirtystudio.co.uk/biotech-tv-interview-with-catherine-pickering/ 2025-09-05T11:19:32+00:00 https://ionctura.threethirtystudio.co.uk/onclive-early-activity-with-roginolisib-supports-ongoing-phase-2-ocule-01-trial-in-metastatic-uveal-melanoma/ 2025-08-21T13:44:23+00:00 https://ionctura.threethirtystudio.co.uk/a-randomised-phase-ii-study-of-roginolisib-in-patients-with-advanced-metastatic-ocular-uveal-melanoma-ocule-01/ 2025-07-29T14:28:47+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-strengthens-medical-and-commercialization-expertise-with-two-non-executive-board-appointments/ 2025-07-29T07:01:29+00:00 https://ionctura.threethirtystudio.co.uk/careers-in-discovery-podcast-lars-van-der-veen-ionctura/ 2025-07-08T10:07:52+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-commences-randomized-phase-i-ii-study-in-non-small-cell-lung-cancer/ 2025-06-03T10:44:45+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-commences-randomized-phase-ii-study-in-metastatic-uveal-melanoma-2/ 2025-06-03T10:31:34+00:00 https://ionctura.threethirtystudio.co.uk/pharma-boardroom-interview-with-catherine-pickering/ 2025-06-03T10:31:06+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-bolsters-leadership-team-with-new-appointments/ 2025-06-03T10:31:00+00:00 https://ionctura.threethirtystudio.co.uk/ionctura_strengthens_leadership_with_appointments_of_chief_business_officer_and_board_chair/ 2025-05-23T15:32:05+00:00 https://ionctura.threethirtystudio.co.uk/bioworld-ioa-244-to-revive-pi3k-delta-inhibitors/ 2025-04-08T10:53:03+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-reaches-new-clinical-milestones-in-uveal-melanoma/ 2024-12-11T10:33:32+00:00 https://ionctura.threethirtystudio.co.uk/drug-target-review-biotech-leader-champions-targeted-cancer-treatments-and-diversity/ 2024-11-26T08:39:54+00:00 https://ionctura.threethirtystudio.co.uk/small-company-big-theme-how-ionctura-is-pursuing-drug-resistance/ 2024-09-24T13:04:52+00:00 https://ionctura.threethirtystudio.co.uk/firstword-pharma-with-fresh-e80m-in-hand-ionctura-looks-to-chart-new-pi3k-path/ 2024-08-22T10:20:07+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-raises-e80m-to-advance-early-stage-rare-eye-cancer-treatment/ 2024-08-22T10:16:37+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-announces-expansion-of-roginolisib-clinical-trial-program-to-nsclc/ 2024-07-09T08:09:23+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-awarded-eur17-5-million-funding-from-the-eic-accelerator-for-clinical-development-of-novel-pancreatic-cancer-therapy/ 2024-07-08T09:53:21+00:00 https://ionctura.threethirtystudio.co.uk/peer-reviewed-translational-research-paves-the-way-for-first-in-class-autotaxin-inhibitor-ioa-289-in-cancer/ 2024-07-08T09:50:38+00:00 https://ionctura.threethirtystudio.co.uk/us-fda-grants-orphan-drug-designation-for-ioncturas-first-in-class-autotaxin-cancer-therapy-2/ 2024-07-08T09:49:27+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-announces-eur80-million-series-b-financing-to-progress-pipeline-through-phase-ii-trials/ 2024-06-27T10:17:54+00:00 https://ionctura.threethirtystudio.co.uk/the-role-of-caf-in-promoting-cancer-cell-proliferation/ 2024-06-11T15:10:19+00:00 https://ionctura.threethirtystudio.co.uk/pharmaphorum-realising-the-potential-of-autotaxin-inhibition-in-cancer/ 2024-06-11T11:59:10+00:00 https://ionctura.threethirtystudio.co.uk/drug-discovery-world-meet-the-researcher-giusy-di-conza-ionctura/ 2024-06-11T11:58:33+00:00 https://ionctura.threethirtystudio.co.uk/labiotech-could-this-be-the-start-of-a-new-era-for-pi3k-drugs/ 2024-06-11T11:58:13+00:00 https://ionctura.threethirtystudio.co.uk/drug-target-review-combining-autotaxin-and-tgf-%ce%b2-inhibitors-in-cancer/ 2024-06-11T11:57:56+00:00 https://ionctura.threethirtystudio.co.uk/immuno-oncology-insights-navigating-the-complexities-of-immunotherapy-unraveling-novel-targets-pathways/ 2024-06-11T11:57:38+00:00 https://ionctura.threethirtystudio.co.uk/pharmaphorum-uveal-melanoma-a-new-generation-of-therapies-offers-hope-for-patients/ 2024-06-11T11:57:01+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-to-present-preclinical-data-on-its-clinical-stage-autotaxin-inhibitor-ioa-289-at-aacr/ 2024-06-11T09:59:21+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-data-at-aacr-demonstrates-unique-mechanism-of-action-for-clinical-stage-autotaxin-inhibitor-ioa-289/ 2024-06-11T09:58:23+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-to-present-at-asco-encouraging-phase-ib-refractory-uveal-melanoma-data-for-first-semi-allosteric-pi3k%ce%b4-inhibitor-ioa-244/ 2024-06-11T09:57:30+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-to-present-at-asco-ioa-244-showing-highly-promising-impact-on-overall-survival-for-patients-with-metastatic-and-refractory-uveal-melanoma/ 2024-06-11T09:28:11+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-expands-advisory-board/ 2024-06-11T09:26:58+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-initiates-phase-ib-pancreatic-cancer-trial-of-next-generation-autotaxin-inhibitor-ioa-289/ 2024-06-11T09:25:48+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-provides-development-update-on-first-in-class-semi-allosteric-pi3k%ce%b4-inhibitor-program/ 2024-06-11T09:21:24+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-announces-publication-of-pioneering-research-describing-the-unique-biological-features-of-roginolisib/ 2024-06-11T09:20:24+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-awarded-uks-mhra-innovation-passport-for-entry-into-innovative-licensing-and-access-pathway-ilap/ 2024-06-11T09:19:24+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-expands-pipeline-and-receives-development-grant-from-health-holland-and-kwf/ 2024-06-11T09:18:17+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-to-present-research-at-leading-scientific-conferences-in-june-2023/ 2024-06-11T09:15:44+00:00 https://ionctura.threethirtystudio.co.uk/new-research-highlights-potential-of-ionctura-strategy-combining-autotaxin-and-tgf-%ce%b2-inhibitors-in-cancer/ 2024-06-11T09:14:38+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-announces-fda-clearance-of-ind-application-for-roginolisib-a-first-in-class-allosteric-modulator-of-pi3k%ce%b4/ 2024-06-11T09:12:49+00:00 https://ionctura.threethirtystudio.co.uk/ionctura-to-present-research-on-roginolisib-and-ioa-359-at-ash/ 2024-06-11T09:08:46+00:00 https://ionctura.threethirtystudio.co.uk/updated-clinical-safety-and-efficacy-data-for-ioncturas-roginolisib-presented-at-esmo-immuno-oncology-congress-2023/ 2024-06-11T09:08:40+00:00